Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02BVW
|
|||
| Drug Name |
FF-10501-01
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1] | |
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1] | Phase 1/2 | [1] | ||
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [1] | ||
| Company |
FUJIFILM Pharmaceuticals U.S.A. Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell differentiation (CD) | Target Info | Stimulator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02193958) Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.